Brown Capital Management - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
Brown Capital Management ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$214,965,332
-16.7%
3,158,004
-0.1%
3.30%
-10.0%
Q2 2023$258,023,614
+6.6%
3,160,892
-3.1%
3.66%
+1.2%
Q1 2023$242,035,750
-11.5%
3,262,377
-1.2%
3.62%
-20.1%
Q4 2022$273,627,657
+17.0%
3,301,492
+301.0%
4.53%
+38.1%
Q3 2022$233,818,000
-19.7%
823,303
-1.9%
3.28%
-15.9%
Q2 2022$291,034,000
-26.8%
839,587
-8.6%
3.90%
-1.5%
Q1 2022$397,673,000
-22.1%
918,328
-6.9%
3.96%
-6.3%
Q4 2021$510,513,000
+5.2%
986,803
-1.5%
4.22%
+6.3%
Q3 2021$485,350,000
-0.5%
1,001,610
-7.6%
3.98%
+7.5%
Q2 2021$488,024,000
-4.7%
1,083,872
-19.2%
3.70%
-3.0%
Q1 2021$512,224,000
+7.7%
1,341,147
-10.5%
3.81%
+16.0%
Q4 2020$475,764,000
+25.6%
1,498,233
-2.0%
3.29%
+4.7%
Q3 2020$378,743,000
-6.3%
1,528,854
-0.2%
3.14%
-9.7%
Q2 2020$404,357,000
+37.0%
1,531,250
-1.6%
3.48%
+1.6%
Q1 2020$295,140,000
-18.1%
1,556,483
-5.2%
3.42%
-0.7%
Q4 2019$360,303,000
+12.4%
1,641,397
+0.2%
3.45%
+10.8%
Q3 2019$320,614,000
-6.2%
1,638,547
-0.0%
3.11%
-4.0%
Q2 2019$341,704,000
+3.0%
1,638,947
-1.9%
3.24%
-3.4%
Q1 2019$331,717,000
+34.6%
1,670,699
-1.9%
3.35%
+13.1%
Q4 2018$246,375,000
-41.6%
1,702,424
-17.7%
2.96%
-22.7%
Q3 2018$422,122,000
+44.0%
2,068,108
+4.4%
3.83%
+27.5%
Q2 2018$293,057,000
-2.5%
1,980,782
-0.4%
3.01%
-11.9%
Q1 2018$300,503,000
+14.5%
1,989,561
-1.8%
3.41%
+7.1%
Q4 2017$262,429,000
+2.4%
2,025,700
-4.4%
3.19%
+2.2%
Q3 2017$256,179,000
+1.5%
2,119,107
-1.3%
3.12%
+0.8%
Q2 2017$252,311,000
+15.6%
2,147,328
-0.0%
3.09%
+6.2%
Q1 2017$218,313,000
-7.3%
2,147,690
-6.3%
2.91%
-15.4%
Q4 2016$235,585,000
-4.8%
2,291,016
+1.4%
3.44%
-5.4%
Q3 2016$247,476,000
-2.9%
2,260,053
+0.0%
3.64%
-9.6%
Q2 2016$254,805,000
+8.3%
2,259,507
-9.2%
4.03%
+3.4%
Q1 2016$235,192,000
+6.6%
2,488,278
+1.5%
3.89%
+12.6%
Q4 2015$220,710,000
-2.1%
2,452,328
+0.6%
3.46%
-10.5%
Q3 2015$225,432,000
-1.2%
2,438,158
+5.2%
3.86%
+2.8%
Q2 2015$228,181,000
-1.8%
2,317,266
-0.0%
3.76%
-2.0%
Q1 2015$232,401,000
+7.9%
2,317,290
-0.6%
3.83%
+3.1%
Q4 2014$215,480,0002,332,0403.72%
Other shareholders
BIO-TECHNE CORP shareholders Q4 2020
NameSharesValueWeighting ↓
Broadcrest Asset Management, LLC 300,000$24,489,00021.05%
Montanaro Asset Management Ltd 388,800$31,737,7445.02%
Sandhill Capital Partners LLC 502,447$41,014,7753.74%
Brown Capital Management 3,160,892$258,023,6143.66%
DF DENT & CO INC 3,275,617$267,388,6403.62%
Ownership Capital B.V. 2,282,104$186,288,1503.26%
Jackson Square Partners, LLC 1,361,789$111,162,8363.24%
STONE RUN CAPITAL, LLC 88,135$7,194,4603.20%
Pembroke Management, LTD 339,591$27,720,8132.99%
Summit Creek Advisors LLC 283,693$23,157,8602.90%
View complete list of BIO-TECHNE CORP shareholders